REG - Hikma Pharmaceutical - Director/PDMR Shareholding

Hikma PharmaceuticalsAnnouncement

17/04/2024 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240417:nRSQ9811Ka&default-theme=true

RNS Number : 9811K  Hikma Pharmaceuticals Plc  17 April 2024

Hikma Pharmaceuticals PLC - Discretionary Share Award

 

LONDON, 17 April 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the
following conditional award under the Hikma Pharmaceuticals PLC 2023 Long Term
Incentive Plan (the "LTIP") to Hafrun Fridriksdottir, a Person Discharging
Managerial Responsibility ("PDMR") of the Company. No consideration was paid
for the grant of the award.

The award under the LTIP was made on 16 April 2024 based on a price of £18.64
per Ordinary Share (being the average mid-market Ordinary Share price for the
5-working day period prior to 9 April 2024, in accordance with the LTIP rules)
(the "LTIP Award"). The vesting of the LTIP Award is subject to the continued
employment of the PDMR, malus and clawback provisions, and the satisfaction of
performance conditions set by the Remuneration Committee of the Company. The
LTIP Award will normally vest on the later of the third anniversary of the
date of grant and the determination of the performance conditions. The LTIP
Award is then subject to an additional two-year holding period.

This notification is made under Article 19(1) of the EU Market Abuse
Regulation 596/2014 as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided
in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by persons discharging
managerial responsibilities

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                                            Hafrun Fridriksdottir
 2   Reason for the notification
 a)  Position/status                                                                 PDMR
 b)  Initial notification /Amendment                                                 Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                                            Hikma Pharmaceuticals PLC
 b)  LEI                                                                             549300BNS685UXH4JI75
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument and identification  Description: Ordinary shares of 10 pence each (Shares)
     code

                                                                                     ID Code: GB00B0LCW083
 b)  Nature of the transaction                                                       Grant of award under the LTIP.

 c)  Price(s) and volume(s)                                                          Price(s)                      Volume(s)
     Nil                                                                                                           LTIP Award: 57,374
 d)  Aggregated information                                                          Price(s): Nil

                                                                                     Volume(s): 57,374
 e)  Date of the transaction                                                         16 April 2024
 f)  Place of the transaction                                                        Outside a trading venue

 

Helen Middlemist

Group Company Secretary

+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGCGDSBSBDGSR